YPN-005 / KT&G Corp - LARVOL DELTA

Antileukemic effect of cyclin-dependent kinase 7 inhibitor; YPN-005 combined with FLT3 inhibitor in FMS-tyrosine kinase 3 -mutated acute myeloid leukemia (ICKSH 2023) - "FLT3-TKIs include midostaurin, gilteritinib, and quizartinib. These results provide preclinical evidence of combined treatment of YPN-005 and FLT3 inhibitor for therapeutic strategies for FLT3-mutated AML. Keyword : FLT3-ITD, CDK7 inhibitor, Mitochondrial dysfunction, Apoptosis"

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Metabolic Disorders • Oncology • ANXA5 • CASP3 • CDK7 • FLT3 • MCL1 • MYC • STAT5

Antileukemic Activity of Ypn-005, a CDK7 Inhibitor, Inducing Apoptosis through c-MYC and FLT3 Suppression in Acute Myeloid Leukemia (ASH 2022) - "Conclusion In conclusion, our data suggest that YPN-005, a CDK7 inhibitor has a potential role in treating AML by inducing apoptosis and suppressing c-MYC and FLT3/STAT5. The antileukemic property of YPN-005 needs to be further evaluated in FLT3-mutated AML."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • ANXA5 • FLT3 • MCL1 • MYC • STAT5

Antileukemic activity of YPN-005, a CDK7 inhibitor, inducing apoptosis through c-MYC and FLT3 suppression in acute myeloid leukemia. (PubMed, Heliyon) - "Phosphorylated FLT3/Signal transducer and activator of transcription 5 (STAT5) was decreased and FLT3/STAT5 was downregulated with YPN-005 treatment. Our data suggest that YPN-005 has a role in treating AML by suppressing c-MYC and FLT3."

Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3 • MYC • STAT5

Discovery of a novel CDK7 inhibitor YPN-005 in small cell lung cancer. (PubMed, Eur J Pharmacol) - "We developed a potent inhibitor of cyclin-dependent kinase 7 (CDK7), designated YPN-005, and sought to determine whether it showed any anticancer effects in SCLC cells, cisplatin or etoposide-resistant cells, or organoids derived from SCLC patients. Finally, YPN-005 showed potent anticancer effects in organoids derived from SCLC patients compared to another CDK7 inhibitor, THZ1. Therapeutic targeting of CDK7 in SCLC might be suitable for clinical investigation, and YPN-005 may be a promising therapeutic option for primary SCLC and SCLC with acquired resistance to conventional therapy."

Journal • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor